

Neurotech Presentation at NWR Virtual Healthcare Conference

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, will today present at the NWR Virtual Healthcare Conference.

CEO & Managing Director Dr Anthony Filippis will present at **3:20pm AEDT today**.

The Company's refined strategy seeks to accelerate timeframes to revenue generation and commercialisation opportunities. Neurotech has a unique and valuable portfolio well positioned for near-term value creation by:

- Advancing regulatory pathways – targeting TGA approvals in Australia and progressing our IND submissions in the USA.
- Developing strategic partnerships to align with key players in the industry to expand our market reach.
- Driving early revenue opportunities – leveraging the compelling clinical data to date and regulatory pathways to make a meaningful difference for patients and grow shareholder value.

Dr Anthony Filippis commented *"I take great pride in open communication, and as part of that commitment, I am excited to keep you informed and engaged in the Company's journey. To provide further insight, I am pleased to share our updated corporate presentation for today's NWR Virtual Healthcare Conference, which outlines our refined strategy and near-term catalysts that will unlock Neurotech's full potential. We are building momentum, and I look forward to keeping you updated as we execute our vision and enter into a transformative phase for Neurotech."*

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: https://us02web.zoom.us/webinar/register/WN_-GvhLfJnTeeR878af88qSw

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au

For more information please visit: <https://nwrcommunications.com/healthconf>

A copy of the presentation is attached.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

About Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

About NTI164

NTI164 is a proprietary drug formulation derived from unique cannabis strains with a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. Clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.



Advancing Neuroscience Transforming Lives



Dr Anthony Filippis
Chief Executive Officer & Managing Director

Corporate Overview

March 2025

Forward-Looking Statements

This presentation contains **forward-looking statements** within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such as ‘could,’ ‘would,’ ‘may,’ ‘potentially,’ ‘suggest,’ ‘believes,’ ‘expects,’ ‘should,’ ‘intends,’ ‘plans,’ ‘forecasts,’ and similar words or expressions.

Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including without limitation statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, pricing, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.

The Company does not warrant any of the forward-looking statements in this presentation, and investors are advised to interpret such statements in the context of other available sources of information and with the assistance of expert advisors as appropriate.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Drug development is inherently risky, and only a small proportion of research and development programs lead to a marketed product. Factors which could change the Company’s expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; changes in the competitive landscape pertaining to our drug development candidates; the timely availability of necessary capital to pursue our business objectives; changes in the public policy environment in one or more countries in which we operate or may seek to operate which disfavour our business; our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services; and other factors, including the COVID-19 pandemic and the conflict in Ukraine.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, and although they reflect our current views as at the date of this presentation, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to pursue any specific strategy or plan outlined herein, or to deliver any specific outcome that may be implied or inferred.


Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Neurotech International (ASX: NTI) is a clinical stage biotech company

- **NTI164**, is an orally available cannabinoid therapy for the treatment of neurological disorders
 - **Autism Spectrum Disorder (ASD)**
 - Positive clinical data from single arm NTIASD01 phase I/II study
 - Positive clinical data from double-blind, randomised and controlled-to-open-label HARMONY phase II/III study
 - Ongoing non-clinical toxicology and human PK studies
 - **Rett Syndrome (RTT)**
 - Positive clinical data from single arm NTIRTT01 phase I/II study
 - Orphan Drug Designation in US and Europe
 - **Pediatric acute-onset neuropsychiatric syndrome (PANS)/pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS)**
 - Positive clinical data from single arm NTIPANS01 study
- **NTI164 is a clinical-stage asset with substantial commercial opportunity**
 - Approximately \$12.6B TAM opportunity across all indications
 - Epidiolex priced at ~ US\$33K per treatment year; with 2024 net product sales of US\$972M
 - NTI164 applicable to several other neurological disorders, including and Cerebral Palsy
 - Potential for applications in other indications
- **Neurotech has strong corporate fundamentals**
 - Highly-experienced Board, management team and advisors
 - Financing of \$10M in April 2024 leaves the company with \$5.9M at 31 December 2024, \$2.44M R&D Tax Incentive January 2025, leaving the company well funded for ongoing operations
 - 2025, pivot company for commercial success



Neurotech’s pipeline comprises clinical programs in neurological and rare neurological disorders of children where neuroinflammation is involved



Targeting large markets where there is a clear unmet need

	Incidence rate	Gender prevalence	Genetic cause	Onset of symptoms	Global cases
<div>Autism Spectrum Disorder</div> <div>>\$3B*</div>	<div>~1 in 36 children aged 8 in US</div> <div><small>Surveillance Summaries Mar 2023 72(2)1-14</small></div>	<div>4x more common in boys</div>	<div>100's of genes implicated. Influenced by genetic and environmental factors</div>	<div>Appear before age 3</div> <div>Signs as early as 12-18 months</div>	<div>Estimated ~62M cases globally</div> <div><small>Lancet Vol 12, Issue 2, P111-121, Feb 2025</small></div>
<div>Rett Syndrome</div> <div>>\$2B#</div>	<div>~1 in 10K-15K live female births</div>	<div>Primarily affects girls, boys often do not survive infancy</div>	<div>95% of cases caused by mutations in the MECP2 gene on X chromosome</div>	<div>Appear at 6-18 months of age</div>	<div>Estimated 350K+ cases in children</div>
<div>PANDAS/ PANS</div> <div>~\$1.4B</div>	<div>~1 in 12K children aged 3-12</div>	<div>2:1 boys to girls</div>	<div>Unknown</div> <div>Autoimmune responses triggered by infections</div>	<div>Signs from 1-13</div> <div>Peak onset 6-7 years of age</div>	<div>~14K US/EU global cases not well defined</div> <div><small>Wald et al Front Pediatr 2023 Sep 21;11:1170379</small></div>

*US/EU based on Market Reports (Grandview Research, Virtue Market Research) on current drugs used #US market only DAYBUE™ (trofinetide) can be up to US\$1,000 per day.
Source: Various sources, Neurotech market estimates/presentations, ASX Release 12 August 2024 based on various data sources, Neuren Pharma presentation dated 28 August 2023.




What is NTI164?

- Cannabinoid derived therapy
 - Proprietary formulation with a novel combination of cannabinoids
 - Patents cover composition, use and formulations
- Targeted therapy
 - Designed to target neuroinflammation by suppressing a wide range of inflammatory cytokines, improving neuronal viability and overall health
 - Directly addresses the underlying causes, not just the symptoms of neurological disorders such as ASD, Rett Syndrome and PANS/PANDAS
- Safe and effective in preclinical and clinical studies
 - Exceptional safety profile
 - Delivers long-term therapeutic benefits



Transformative breakthrough in neurological and rare neurological disorders


NTI164 has shown compelling evidence of clinical efficacy



Clinical trial results			
	ASD	Rett	PANS
CGI-I (overall improvement)	84%*↑	93%*↑	87%*↑
CGI-S (severity of illness)	32%*↓	24%*↓	31%*↓


*p<0.001; ^ 4 core domains of interest (communication skills, mental alertness, socialisation/eye contact and anxiety)

Pivot company towards revenue and commercialisation to grow shareholder value

























NTI internal timeframe estimates

US 'go to market' strategy



The competitive landscape is not crowded with few approved therapies

	Early Development	Late Development	Approved
Autism Spectrum Disorder <i>Several off-label use of other neuropsychiatric drugs which have side effects</i>	   	 NTI164     	   
Rett Syndrome <i>Only a few Phase I/II clinical trials underway, with late development failure</i>	 NTI164  	 Blarcamesine	 
PANDAS/PANS <i>Emerging area, strong patient advocacy</i>	 NTI164	 Panzyga	No approved drugs

Risperdal firstly developed by Janssen-Cilag & Ablify by Otsuka

Originally approved for Schizophrenia, now used for irritability and aggression in children > 5-6 yrs with ASD

Daybue, the first treatment approved in Rett Syndrome. 61% of patients showed no improvement, with no data on which symptoms improve. Costs ~US\$350K, selling US\$348M in 2024

In Jan 2024, Blarcamesine failed to meet primary endpoint in Phase II/III clinical trial





Antibiotics commonly used. IVIG (Panzyga) approved for other indications shown to ease symptoms

Neurotech ahead of the curve in recognising this devastating disorder

Not exhaustive list, NTI internal analysis, BioKnow ASD landscape Feb 2025



The commercial opportunity for NTI164 is substantial, with a potential market size of >US\$10 billion, reflecting favorable pricing dynamics

Comparator Revenues (2022-24)

Company	Product	2024 (US\$)	2023 (US\$)	2022 (US\$)
 Jazz Pharmaceuticals	 Epidiolex® (cannabidiol)	\$972M	\$845M	\$731M
 ACADIA	 Daybue™ (trofinetide)	\$348M	\$177M	N/A


Epidiolex ~US\$1B in annual sales
at 15% growth YoY

Comparator Pricing











Company	Product	Annual Cost (US\$)
 Jazz Pharmaceuticals	 Epidiolex® (cannabidiol)	~\$33K
 ACADIA	 Daybue™ (trofinetide)	~\$350K

Conservative NTI164 pricing at \$24k in Aus/EU;
\$49K in US; \$12K in ROW per patient per year

NTI164 Commercial Opportunity



Market comparators provide a strong precedent for NTI164

Market comparators		
Company	Comparable pipeline	Market Cap
 Jazz Pharmaceuticals	 Epidiolex® (cannabidiol, approved)	~ US\$8.5B
 ACADIA	 Daybue™ (trofinetide) (approved)	~ US\$2.9B
 neuren pharmaceuticals	NNZ-2591 Phase 2 data including Angelman, Phelan McDermid, Pitt Hopkins	~AU\$1.6B
 anavex LIFE SCIENCES Corp.	Anavex 2-73 (Blarcamesine) Phase 2/3 for Rett Syndrome (failed Jan 2024) Phase 2/3 for ASD	~US\$790M
 HARMONY BIOSCIENCES	Zyn-002 (cannabidiol gel) Phase 3 for Fragile X Syndrome Phase 3 for epilepsy	~US\$2B
 Taysha GENE THERAPIES	Gene therapies for monogenic CNS diseases Phase 1/2 for Rett Syndrome	~US\$357M
 NEUROGENE	Phase 1/2 for Rett Syndrome Phase 1/2 for Batten Disease	~US\$235M
 Neurotech International	Phase 2/3 data in ASD Phase 1/2 data in Rett Syndrome Phase 1/2 data in PANDAS/PANS	~AU\$39M

Neurotech has compelling clinical data in ASD, Rett Syndrome and PANDAS/PANS and is valued at ~AU\$39M

Market cap as at 19 March 2025 AEDT, non-exhaustive list

The company will commence a broad outreach program to socialise and nurture potential future partners for NTI164

Typical Structure of Pharma Partnering Transactions

Upfront

- Payment(s) at the time signing a deal
- Usually not ‘at risk’
- May include an equity component

Milestones

- Payment(s) during the partnership, linked to pre-defined development and commercial outcomes
- ‘At risk’ payments – not made if the relevant objectives are not met

Royalties

- A share of net sales (or sometimes profit) that flows from the licensee to the licensor
- Often the greatest source of economic value in the transaction
- Value depends on successful commercialisation of the product




















Benchmarks for Phase II/III Neuro Disease Partnering Transactions (2016 – 2025 YTD) (n=64)

	Low	Median	High
Upfront Cash/Equity (US\$M)	3	40	1000
Milestones (US\$M)	120	467	1,900
Royalties	5%	9%	12%

The capability and commitment of a partner to develop and commercialise the product can be as crucial as the financial terms of the transaction

Source: DealForma; Neurotech analysis

Partnering opportunity for NTI164 is substantial, with benchmark transactions suggesting significant value potential

Licensing Transactions						
Licensee	Licensor	Key Asset(s)	Key Indication(s)	Stage	Date	Deal Value (US\$)
 NOVARTIS		PTC518	Huntington's disease	Phase II	Nov 2024	\$2.9B
		ABV-1504/1505	ADHD, depression	Phase II	Nov 2023	\$667M
		Trofinetide (xUS), NNZ-2591	Rett syndrome (ex-US)	Phase II	Jul 2023	\$931M
	MAZE THERAPEUTICS	MZE-001	Pompe disease	Phase I	May 2023	\$750M
		SAN711	Essential tremor	Phase I	Nov 2024	\$582M
		CAP-1002 (United States)	Duchenne muscular dystrophy	Phase II	Jan 2022	\$735M
		Mavoglurant	Autism, mood disorders	Phase II	Jan 2023	\$270M
M&A Transactions						
Acquirer	Target	Key Asset(s)	Key Indication(s)	Stage	Date	Deal Value (US\$)
		Olorinab (cannabinoid)	Immuno-inflammatory disorders	Phase II	Dec 2021	\$6.7B
		Epidiolex (cannabinoid)	Dravet, Lennox Gastaut syndromes	Approved	Feb 2021	\$7.2B
		Skyclarus	FA, neurological disorders	Approved	Jul 2023	\$7.3B

Source: Non-exhaustive list, DealForma, company press releases, Neurotech research

Neurotech Board brings extensive international experience in drug development, finance and commercialisation



Mr Mark Davies
Board Chair

20 years experience in trading, finance, investment banking and providing corporate advice



Dr Anthony Filippis
Managing Director & CEO

25 years of life sciences leadership experience, with a focus on BD, corporate strategy, and operations



Mr Max Johnston
Non-Executive Director

Over 40 years pharma leadership. Over 10 years as Chief Executive Officer of Johnson and Johnson Pacific. Sits on several ASX listed Boards



Dr Tom Duthy
Executive Director

Over 20 years of direct financial market and executive-level/Board experience with ASX listed companies



Mr Gerald Quigley
Non-Executive Director

Qualified Pharmacist. Leading media health commentator heard each week on television and radio stations across Australia



Neurotech’s clinical advisory/KOL committee provides extensive expertise in clinical development



Professor Carolyn Ellaway
Head, Metabolic Genetics

Children’s Hospital,
Westmead, Sydney NSW

Rett Syndrome



Professor Michael Fahey
Head, Paediatric Neurology

Monash Children’s Hospital
Clayton, Melbourne, Victoria

Austim Spectrum Disorder



Professor Russell Dale
Head, Paediatric Neurology

Children’s Hospital,
Westmead, Sydney, NSW

PANS/PANDAS



Professor Jennifer Frankovic
Clinical Professor, Paediatrics

Stanford Medicine
Children’s Health, Menlo Park, CA

General Paediatrics
PANS/PANDAS



Dr Terence Thomas
Head, Neurology

Singapore General Hospital,
Singapore

Paediatric Neurology
Neuroimmunology



Neurotech financial position and value drivers

Corporate Fundamentals

Market Capitalisation:	~AU\$ 39M
Primary Listing:	ASX: NTI
Shares on Issue:	1.04 Billion

Financial Position

Cash Balance (31 Dec 24):	AU\$ 5.9 Million
R&D Tax Incentive (31 Jan 25)	AU\$2.44M

Shareholders

Top 40	58.95%
--------	--------


Analyst Coverage



ASX:NTI

\$0.037 (-2.632%)

Last updated 4:02 PM 19 Mar 2025



Huge Market Potential

Addressing high-growth neurological markets

Proven science and de-risked programs

Positive clinical results supporting efficacy & safety




Clear Commercial Pathway

Strong IP, strategic partners & regulatory progress

Strong Leadership & Vision

Experienced team driving innovation and execution

Value-driving catalysts on the horizon for Neurotech

CY2025		
R&D Tax Incentive - \$2.44m	1Q CY2025	
Manufacturing update – New partnership with ECC	1Q CY2025	
Neurotech Receives Positive Opinion for Orphan Designation in Rett Syndrome for NTI164 in Europe	1Q CY2025	
Completion of Phase 1 human PK trial	1H CY2025	
Completion of IND enabling GLP 28 day toxicology study	1H CY2025	
Initiation of 9 month GLP NDA enabling toxicology studies	1H CY2025	
Type D meeting with US FDA	1H CY2025	
TGA Rett Syndrome provisional determination	2H CY2025	
IND submission in Autism Spectrum Disorder & Rett Syndrome	2H CY2025	
IND approval for Autism Spectrum Disorder and Rett Syndrome	2H CY2025	

What are families and clinicians saying about NTI164?

"I feel as though my son just finally work up"

"From 20 meltdowns a day to maybe 1"

"He's going to school camp for the first time ever"

"I've got my son back"

"I used to get phone calls from his school every other day to come and pick him up because of his behavior. I haven't had one since starting the oil"

"I can tell she's more aware of what's going on around her and is trying harder to communicate"

"She's calmer and happier, like she's less frustrated because she can express herself better"

"She's deliberately using her eyes to tell us what she wants now - it's not just looking, it's intentional and purposeful"

"In my view, results obtained with NTI164 are truly remarkable and unprecedented. My team and I are excited to be part of this life-changing program."

Professor Carolyn Ellaway



"Over the next 12 months on NTI164, I observed continuous progress, with his response being unequivocal and impressive."

Professor Russell Dale



"There is an urgent need for safe and effective treatments for children with autism, and NTI164 is showing strong potential to fill this gap in care."

Professor Michael Fahey



Source: Family and clinician statements



Neurotech

International

Contact Details

Neurotech Investor Relations
info@neurotechinternational.com

This presentation has been authorised by the Board of Neurotech International Limited

www.neurotechinternational.com

Neurotech International Limited (ASX: NTI)